









市場行情
/
股票
/
nasdaq-pfe
/

輝瑞

PFE

25.270USD

0.0000.00%

收盤 01/08, 16:00（美東）報價延遲15分鐘

143.69B總市值

14.61本益比TTM



輝瑞

25.270

0.0000.00%

概覽公司財務分析

概覽

公司

財務

分析

關於輝瑞公司

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

輝瑞簡介



公司代碼PFE

公司名稱Pfizer Inc

上市日期Feb 22, 2080

CEOBourla (Albert)

員工數量81000

證券類型Ordinary Share

年結日Feb 22

公司地址66 Hudson Boulevard East

城市NEW YORK

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編10001-2192

電話12127332323

網址https://www.pfizer.com/

公司代碼PFE

上市日期Feb 22, 2080

CEOBourla (Albert)

輝瑞公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+35552.00%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+12289.00%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+7298.00%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-553.00%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+19457.00%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

+30962.00%

Mr. Aamir Malik

Executive Vice President, Chief US Commercial Officer

29.55K

+29174.00%

Ms. Payal Sahni

Executive Vice President, Chief People Experience Officer

24.85K

+1543.00%

Dr. Scott Gottlieb, M.D.

Independent Director

10.00K

Mr. Cyrus Taraporevala

Independent Director

10.00K

名稱

名稱/職務

職務

持股

持股變動

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+35552.00%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+12289.00%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+7298.00%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-553.00%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+19457.00%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

+30962.00%

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Eliquis alliance revenues and direct sales

2.02B

12.10%

Prevnar family

1.74B

10.46%

Vyndaqel family

1.59B

9.55%

Paxlovid

1.23B

7.36%

Comirnaty

1.15B

6.91%

其他

8.93B

53.62%

地區USD

名稱

營收

佔比

United States

10.69B

64.19%

Developed Markets

3.70B

22.19%

Emerging Markets

2.27B

13.61%

業務

地區

業務USD

名稱

營收

佔比

Eliquis alliance revenues and direct sales

2.02B

12.10%

Prevnar family

1.74B

10.46%

Vyndaqel family

1.59B

9.55%

Paxlovid

1.23B

7.36%

Comirnaty

1.15B

6.91%

其他

8.93B

53.62%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.35%

State Street Investment Management (US)

5.26%

BlackRock Institutional Trust Company, N.A.

5.17%

Geode Capital Management, L.L.C.

2.27%

Norges Bank Investment Management (NBIM)

1.65%

其他

76.30%

持股股東

佔比

The Vanguard Group, Inc.

9.35%

State Street Investment Management (US)

5.26%

BlackRock Institutional Trust Company, N.A.

5.17%

Geode Capital Management, L.L.C.

2.27%

Norges Bank Investment Management (NBIM)

1.65%

其他

76.30%

股東類型

持股股東

佔比

Investment Advisor

33.36%

Investment Advisor/Hedge Fund

23.13%

Research Firm

2.99%

Pension Fund

2.47%

Bank and Trust

1.76%

Sovereign Wealth Fund

1.72%

Insurance Company

1.27%

Hedge Fund

0.93%

Holding Company

0.05%

其他

32.33%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

4669

3.85B

67.65%

-88.11M

2025Q3

4830

3.80B

66.84%

-140.11M

2025Q2

4945

3.85B

67.75%

-89.09M

2025Q1

5074

3.86B

67.90%

-51.97M

2024Q4

5153

3.84B

67.74%

-83.26M

2024Q3

5005

3.85B

67.99%

-51.77M

2024Q2

5026

3.84B

67.75%

-120.77M

2024Q1

5032

3.89B

68.71%

-120.39M

2023Q4

5089

3.97B

70.25%

-96.67M

2023Q3

4952

4.00B

70.89%

-71.80M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

531.51M

9.35%

+833.15K

+0.16%

Sep 30, 2025

State Street Investment Management (US)

299.09M

5.26%

+2.79M

+0.94%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

294.15M

5.17%

+5.26M

+1.82%

Sep 30, 2025

Geode Capital Management, L.L.C.

129.01M

2.27%

+1.54M

+1.20%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

93.65M

1.65%

+5.87M

+6.68%

Jun 30, 2025

Wellington Management Company, LLP

60.46M

1.06%

-16.54M

-21.48%

Sep 30, 2025

State Farm Insurance Companies

57.66M

1.01%

+71.50K

+0.12%

Sep 30, 2025

MFS Investment Management

54.96M

0.97%

-17.80M

-24.46%

Sep 30, 2025

BlackRock Asset Management Ireland Limited

52.35M

0.92%

-2.30M

-4.21%

Sep 30, 2025

BlackRock Investment Management (UK) Ltd.

50.76M

0.89%

+1.88M

+3.85%

Sep 30, 2025

持股ETF



更新時間: 12月1日週一

機構名稱

佔比

VanEck Pharmaceutical ETF

10.43%

First Trust NASDAQ Pharmaceuticals ETF

7.73%

Franklin US Dividend Booster Index ETF

7.39%

First Trust Morningstar Dividend Leaders Index Fund

6.54%

WBI Power Factor High Dividend ETF

4.87%

Invesco Pharmaceuticals ETF

4.84%

Coastal Compass 100 ETF

4.8%

iShares U.S. Pharmaceuticals ETF

4.43%

Amplify Weight Loss Drug & Treatment ETF

4.14%

Roundhill GLP-1 & Weight Loss ETF

3.73%

VanEck Pharmaceutical ETF

佔比10.43%

First Trust NASDAQ Pharmaceuticals ETF

佔比7.73%

Franklin US Dividend Booster Index ETF

佔比7.39%

First Trust Morningstar Dividend Leaders Index Fund

佔比6.54%

WBI Power Factor High Dividend ETF

佔比4.87%

Invesco Pharmaceuticals ETF

佔比4.84%

Coastal Compass 100 ETF

佔比4.8%

iShares U.S. Pharmaceuticals ETF

佔比4.43%

Amplify Weight Loss Drug & Treatment ETF

佔比4.14%

Roundhill GLP-1 & Weight Loss ETF

佔比3.73%

分紅派息



近5年累計派現 36.47B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Dec 12, 2025

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 06, 2026 going ex on Jan 23, 2026

Jan 23, 2026

Mar 06, 2026

Jan 23, 2026

Oct 09, 2025

PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025

Nov 07, 2025

Dec 01, 2025

Nov 07, 2025

Jun 25, 2025

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025

Jul 25, 2025

Sep 02, 2025

Jul 25, 2025

Apr 23, 2025

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025

May 09, 2025

Jun 13, 2025

May 09, 2025

Dec 12, 2024

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025

Jan 24, 2025

Mar 07, 2025

Jan 24, 2025

Oct 09, 2024

PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024

Nov 08, 2024

Dec 02, 2024

Nov 08, 2024

Jun 26, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024

Jul 26, 2024

Sep 03, 2024

Jul 26, 2024

Apr 24, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024

May 10, 2024

Jun 14, 2024

May 09, 2024

Dec 14, 2023

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024

Jan 26, 2024

Mar 01, 2024

Jan 25, 2024

Oct 04, 2023

PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023

Nov 10, 2023

Dec 04, 2023

Nov 09, 2023

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

輝瑞的前五大股東是誰？



輝瑞的前五大股東如下：
The Vanguard Group, Inc.
持有股份：531.51M
佔總股份比例：9.35%。
State Street Investment Management (US)
持有股份：299.09M
佔總股份比例：5.26%。
BlackRock Institutional Trust Company, N.A.
持有股份：294.15M
佔總股份比例：5.17%。
Geode Capital Management, L.L.C.
持有股份：129.01M
佔總股份比例：2.27%。
Norges Bank Investment Management (NBIM)
持有股份：93.65M
佔總股份比例：1.65%。